McKnight · Lancet (London, England) 2012 · systematic review and meta-analysis · n=385 studies

Lithium toxicity profile: a systematic review and meta-analysis.

Cited 882 times in the scientific literature.

Level 1 - systematic review of randomized trials

Systematic review and meta-analysis of randomized controlled trials and observational studies

PubMed 22265699 · doi:10.1016/S0140-6736(11)61516-X · record verified 2026-08-27

What was done

Authors conducted a systematic review and meta-analysis of randomized controlled trials, cohort studies, case-control studies, and case reports assessing lithium toxicity in patients with mood disorders. Searches encompassed electronic databases, specialist journals, reference lists, textbooks, and conference abstracts. Evaluated outcomes were renal, thyroid, and parathyroid function, weight change, skin disorders, hair disorders, and teratogenicity across 385 included studies selected from 5,988 screened abstracts.

What was found

Glomerular filtration rate showed a non-significant reduction of -6.22 mL/min (95% CI -14.65 to 2.20, p=0.148), whereas urinary concentrating ability was reduced by 15% of normal maximum (weighted mean difference -158.43 mOsm/kg, 95% CI -229.78 to -87.07, p<0.0001). Renal replacement therapy was documented in 18 of 3,369 patients (0.5%). Lithium was associated with increased clinical hypothyroidism compared to placebo (OR 5.78, 95% CI 2.00 to 16.67, p=0.001) and elevated thyroid stimulating hormone by an average of 4.00 iU/mL (95% CI 3.90 to 4.10, p<0.0001). Treatment increased blood calcium (+0.09 mmol/L, 95% CI 0.02 to 0.17, p=0.009) and parathyroid hormone (+7.32 pg/mL, 95% CI 3.42 to 11.23, p<0.0001). Lithium was associated with more weight gain than placebo (OR 1.89, 95% CI 1.27 to 2.82, p=0.002) but less than olanzapine (OR 0.32, 95% CI 0.21 to 0.49, p<0.0001). No statistically significant increased risk was observed for congenital malformations, alopecia, or skin disorders.

Why it matters

This comprehensive synthesis clarifies the organ-specific risks of lithium, showing that while end-stage renal failure is uncommon, endocrine perturbations including hyperparathyroidism and hypothyroidism are frequent and require routine monitoring.

Limits

The analysis pools heterogeneous study designs ranging from randomized trials to case reports. Total patient counts are not provided in the abstract for most outcomes, and teratogenic risk remains uncertain.

Cited by